Last reviewed · How we verify
Clopidogrel 75
Clopidogrel irreversibly inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor, preventing blood clots.
Clopidogrel irreversibly inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor, preventing blood clots. Used for Acute coronary syndrome (unstable angina, NSTEMI, STEMI), Secondary prevention of atherothrombotic events in patients with recent myocardial infarction, stroke, or peripheral arterial disease, Coronary artery stent thrombosis prevention.
At a glance
| Generic name | Clopidogrel 75 |
|---|---|
| Sponsor | US Department of Veterans Affairs |
| Drug class | P2Y12 receptor antagonist / Thienopyridine antiplatelet agent |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Clopidogrel is a thienopyridine prodrug that requires hepatic metabolism to its active form. The active metabolite binds irreversibly to the P2Y12 receptor on platelet surfaces, blocking adenosine diphosphate (ADP)-induced platelet activation and aggregation. This antiplatelet effect reduces thrombotic events in patients at risk for cardiovascular complications.
Approved indications
- Acute coronary syndrome (unstable angina, NSTEMI, STEMI)
- Secondary prevention of atherothrombotic events in patients with recent myocardial infarction, stroke, or peripheral arterial disease
- Coronary artery stent thrombosis prevention
Common side effects
- Bleeding
- Dyspepsia
- Diarrhea
- Rash
- Thrombotic thrombocytopenic purpura (TTP)
Key clinical trials
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- SIMPLAAFY Clinical Trial (NA)
- INdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT) (NA)
- Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention (PHASE4)
- STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clopidogrel 75 CI brief — competitive landscape report
- Clopidogrel 75 updates RSS · CI watch RSS
- US Department of Veterans Affairs portfolio CI